At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 892 enrolled
Drug / intervention
Eptinezumab +1 moredrug
Likely dose
Eptinezumab 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
In Brief
A Phase 3 clinical trial evaluating Eptinezumab and Placebo for Migraine. Completed, enrolled 892 participants across 138 sites in 17 countries.
Detailed Summary
Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesBelgium, Bulgaria, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Poland, Russia, Slovakia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJun 2020
Primary CompletionJul 2021
Study CompletionSep 2022
TodayJul 2026
First PostedJun 5, 2020
Enrollment StartJun 1, 2020
Primary CompletionJul 15, 2021
Study CompletionSep 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.1 years ago
Interventions
Eptinezumabdrug
Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
Placebodrug
concentrate for solution for infusion, intravenously